A Phase III, Randomized, Double-Blind, Placebo Controlled Clinical Trial Evaluating the Benefits and Mechanism Of Action Of Angiotensin-II Receptor Blocker On Cardiovascular Remodeling In Patients With Repaired Coarctation Of Aorta
Mayo Clinic
Summary
The purpose of this study is to evaluate the effectiveness and mechanism of action of Losartan in the treatment of coarctation of aorta.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * B/S1 hypertension * SBP 100-139 average based on 3 office measurements. * Age 18 or Older * Previous COA Repair Exclusion Criteria: * Currently on beta blocker (BB) therapy * Pregnancy/lactating * eGFR\<30 * Hyperkalemia (serum potassium \>5.5mmol/L) * Severe Aortic or Mitral valve stenosis or regurgitation * Epicardial CAD diagnosis * Received antihypertensive medications within the past year
Interventions
- DrugLosartan
50mg administered orally once daily for 52 weeks.
- DrugAmlodipine
5mg Amlodipine administered orally once daily for 52 weeks.
- DrugPlacebo
Oral capsules that contain no active drug ingredients administered orally once daily for 52 weeks.
Location
- Mayo Clinic in RochesterRochester, Minnesota